Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY6 | Q15077 | 2/20 | 0.47 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
| ▸ | HTR2B | P41595 | 1/20 | 0.34 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.33 |
| ▸ | AHR | P35869 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7849167 | 0.81 | HTR2C (0.35) | P2RY6HTR2C | |
| SCHEMBL5559994 | 0.74 | PTGS2 (0.50) | PTGS1PTGS2 | |
| SCHEMBL29663770 | 0.72 | P2RY6 (0.41) | P2RY6 | |
| SCHEMBL1930991 | 0.72 | P2RY6 (0.41) | P2RY6 | |
| SCHEMBL5565980 | 0.69 | PTGS2 (0.45) | P2RY6PTGS1PTGS2AHR | |
| SCHEMBL5981834 | 0.67 | PTGS2 (0.43) | PTGS1PTGS2AHR | |
| SCHEMBL6093787 | 0.65 | PTGS2 (0.68) | P2RY6PTGS1PTGS2 | |
| SCHEMBL216253 | 0.65 | PTGS2 (0.68) | P2RY6PTGS1PTGS2 | |
| SCHEMBL5559765 | 0.65 | PTGS2 (0.37) | PTGS1PTGS2 | |
| SCHEMBL7849593 | 0.65 | PTGS2 (0.35) | PTGS1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070149591-A1 | Compositions of a cyclooxygenase-2 selective inhibitor administered under hypothermic conditions for the treatment of ischemic mediated central nervous system disorders or injury | STEPHENSON DIANE T | 2007-06-28 | — | — | US | disclosed |
| US-20050159419-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a central nervous system stimulant for the treatment of central nervous system damage | PHARMACIA CORPORATION (US) | 2005-07-21 | — | — | US | disclosed |
| US-20050159403-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a calcium modulating agent for the treatment of central nervous system damage | PHARMACIA CORPORATION | 2005-07-21 | — | — | US | disclosed |
| US-20050148589-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a neurotrophic factor-modulating agent for the treatment of central nervous system mediated disorders | PHARMACIA & UPJOHN COMPANY LLC (US) | 2005-07-07 | — | — | US | disclosed |
| US-20050113434-A1 | Compositions of a cyclooxygenase-2 selective inhibitor administered under hypothermic conditions for the treatment of ischemic mediated central nervous system disorders or injury | PHARMACIA CORPORATION | 2005-05-26 | — | — | US | disclosed |
| US-20050113376-A1 | Compositions of a cyclooxygenase-2 selective inhibitor, a xanthine compound and an alcohol for the treatment of ischemic mediated central nervous system disorders or injury | PHARMACIA CORPORATION | 2005-05-26 | — | — | US | disclosed |
| US-20050107387-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a peroxisome proliferator activated receptor agonist for the treatment of ischemic mediated central nervous system disorders | PHARMACIA CORPORATION (US) | 2005-05-19 | — | — | US | disclosed |
| US-20050101629-A1 | Compositions of a chromene cyclooxygenase-2 selective inhibitor and a cholinergic agent for the treatment of reduced blood flow or trauma to the central nervous system | PHARMACIA CORPORATION (US) | 2005-05-12 | — | — | US | disclosed |
| US-20050009733-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a potassium ion channel modulator for the treatment of central nervous system damage | PHARMACIA CORPORATION | 2005-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107387-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a peroxisome proliferator activated receptor agonist for the treatment of ischemic mediated central nervous system disorders | PPARA, PPARG, PTGER2 | P2RY6 447/4885HTR2C 520/4885HTR2B 576/4885 |
| US-20050009733-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a potassium ion channel modulator for the treatment of central nervous system damage | KCNJ2, KCNN2, KCNK2 | P2RY6 250/4885HTR2C 985/4885HTR2B 711/4885 |
| US-20050101629-A1 | Compositions of a chromene cyclooxygenase-2 selective inhibitor and a cholinergic agent for the treatment of reduced blood flow or trauma to the central nervous system | ACHE, CHRNA2, CHRM3 | P2RY6 667/4885HTR2C 196/4885HTR2B 239/4885 |
| US-20050159419-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a central nervous system stimulant for the treatment of central nervous system damage | GAP43, PTGS2, CNR2 | P2RY6 422/4885HTR2C 22/4885HTR2B 47/4885 |
| US-20050113434-A1 | Compositions of a cyclooxygenase-2 selective inhibitor administered under hypothermic conditions for the treatment of ischemic mediated central nervous system disorders or injury | PTGS2, PTGS1, PTGES2 | P2RY6 765/4885HTR2C 693/4885HTR2B 303/4885 |
| US-20070149591-A1 | Compositions of a cyclooxygenase-2 selective inhibitor administered under hypothermic conditions for the treatment of ischemic mediated central nervous system disorders or injury | PTGS2, PTGS1, PTGES2 | P2RY6 765/4885HTR2C 693/4885HTR2B 303/4885 |
| US-20050113376-A1 | Compositions of a cyclooxygenase-2 selective inhibitor, a xanthine compound and an alcohol for the treatment of ischemic mediated central nervous system disorders or injury | XDH, PTGS2, PTGS1 | P2RY6 417/4885HTR2C 260/4885HTR2B 317/4885 |
| US-20050148589-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a neurotrophic factor-modulating agent for the treatment of central nervous system mediated disorders | BDNF, NTRK2, NGF | P2RY6 323/4885HTR2C 117/4885HTR2B 143/4885 |
| US-20050159403-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a calcium modulating agent for the treatment of central nervous system damage | PTGS2, PTGS1, PTGIS | P2RY6 136/4885HTR2C 370/4885HTR2B 414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.